Asia Pacific preventive vaccines market will grow by 13.32% annually with a total addressable market cap of $114.84 billion over 2021-2026 owing to the increasing healthcare expenditure, new development of the vaccines, and rising need for preventive vaccines especially new COVID-19 vaccines.
Highlighted with 58 tables and 51 figures, this 138-page report “Asia Pacific Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity” is based on a holistic research of the entire Asia Pacific preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2016-2019 and provides estimate/forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.
Based on Vaccine Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Live/Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• Recombinant Vector Vaccines
• Other Vaccines
Based on Disease, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Vaccines for Pneumococcal Disease
• Vaccines for Poliovirus
• Vaccines for Hepatitis
• Vaccines for Influenza
• Vaccines for Measles, Mumps, and Rubella (MMR)
• Vaccines for Varicella
• Vaccines for Human Papilloma Virus
• Vaccines for COVID-19
• Vaccines for Other Diseases
Based on Administration, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Intramuscular Route
• Subcutaneous Route
• Oral Route
• Intravenous Injection
• Other Administration Routes
Based on Patient, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Pediatric Vaccines
o Pneumococcal
o Measles, Mumps, and Rubella (MMR)
o Varicella
o Hepatitis
o Poliovirus
o Haemophilus Influenzae B (HIB)
o Other Diseases
• Adult Vaccines
o Influenza
o Cervical Cancer
o Hepatitis
o Zoster
o Other Diseases
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2016-2026. The breakdown of key national markets by Vaccine Type, Disease, and Route of Administration over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific preventive vaccines market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Market 23
2.2 Major Growth Drivers 25
2.3 Market Restraints and Challenges 28
2.4 Emerging Opportunities and Market Trends 31
2.5 Porter’s Fiver Forces Analysis 35
3 Segmentation of Asia Pacific Market by Vaccine Type 39
3.1 Market Overview by Vaccine Type 39
3.2 Live/Attenuated Vaccines 41
3.3 Inactivated Vaccines 42
3.4 Subunit Vaccines 43
3.5 Toxoid Vaccines 44
3.6 Conjugate Vaccines 45
3.7 Recombinant Vector Vaccines 46
3.8 Other Vaccines 47
4 Segmentation of Asia Pacific Market by Disease 48
4.1 Market Overview by Disease 48
4.2 Vaccines for Pneumococcal Disease 50
4.3 Vaccines for Poliovirus 51
4.4 Vaccines for Hepatitis 52
4.5 Vaccines for Influenza 53
4.6 Vaccines for Measles, Mumps, and Rubella (MMR) 54
4.7 Vaccines for Varicella 55
4.8 Vaccines for Human Papilloma Virus 56
4.9 Vaccines for COVID-19 57
4.10 Vaccines for Other Diseases 60
5 Segmentation of Asia Pacific Market by Administration 61
5.1 Market Overview by Administration 61
5.2 Intramuscular Route 63
5.3 Subcutaneous Route 64
5.4 Oral Route 65
5.5 Intravenous Injection 66
5.6 Other Administration Routes 67
6 Segmentation of Asia Pacific Market by Patient 68
6.1 Market Overview by Patient 68
6.2 Pediatric Vaccines 70
6.3 Adult Vaccines 72
7 Asia-Pacific Market 2020-2026 by Country 74
7.1 Overview of Asia-Pacific Market 74
7.2 China 77
7.3 Japan 80
7.4 India 84
7.5 Australia 87
7.6 South Korea 90
7.7 Rest of APAC Region 93
8 Competitive Landscape 95
8.1 Overview of Key Vendors 95
8.2 New Product Launch, Partnership, Investment, and M&A 98
8.3 Company Profiles 99
AstraZeneca plc 99
Bavarian Nordic A/S 102
China National Biotec Group Company Ltd. 105
CSL Ltd. 107
Daiichi Sankyo Co. Ltd 109
Emergent BioSolutions Inc. 111
GlaxoSmithKline plc 113
Johnson & Johnson 117
Merck & Co. 119
Moderna Inc. 121
Novavax, Inc. 122
Pfizer Inc. 124
Sanofi SA 128
Takeda Pharmaceutical Co. Ltd. 130
9 Investing in Asia Pacific Market: Risk Assessment and Management 132
9.1 Risk Evaluation of Asia Pacific Market 132
9.2 Critical Success Factors (CSFs) 135
Related Reports and Products 138
Table 1. Snapshot of Asia Pacific Preventive Vaccines Market in Balanced Perspective, 2020-2026 17
Table 2. Growth Rate of World GDP, 2020-2022 22
Table 3. Main Product Trends and Market Opportunities in Asia Pacific Preventive Vaccines Market 31
Table 4. Asia Pacific Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 39
Table 5. Asia Pacific Preventive Vaccines Market by Disease, 2016-2026, $ mn 48
Table 6. COVID-19 Vaccines Authorized for Emergency Use or Approved for Full Use, as of April 2021 58
Table 7. Asia Pacific Preventive Vaccines Market by Administration, 2016-2026, $ mn 61
Table 8. Asia Pacific Preventive Vaccines Market by Patient, 2016-2026, $ mn 68
Table 9. Asia Pacific Preventive Vaccines Market: Pediatric Vaccines by Disease, 2016-2026, $ mn 71
Table 10. Asia Pacific Preventive Vaccines Market: Adult Vaccines by Disease, 2016-2026, $ mn 73
Table 11. APAC Preventive Vaccines Market by Country, 2016-2026, $ mn 75
Table 12. China Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 78
Table 13. China Preventive Vaccines Market by Disease, 2016-2026, $ mn 78
Table 14. China Preventive Vaccines Market by Administration, 2016-2026, $ mn 79
Table 15. Japan Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 82
Table 16. Japan Preventive Vaccines Market by Disease, 2016-2026, $ mn 82
Table 17. Japan Preventive Vaccines Market by Administration, 2016-2026, $ mn 83
Table 18. India Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 85
Table 19. India Preventive Vaccines Market by Disease, 2016-2026, $ mn 85
Table 20. India Preventive Vaccines Market by C Administration, 2016-2026, $ mn 86
Table 21. Australia Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 88
Table 22. Australia Preventive Vaccines Market by Disease, 2016-2026, $ mn 88
Table 23. Australia Preventive Vaccines Market by Administration, 2016-2026, $ mn 89
Table 24. South Korea Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 91
Table 25. South Korea Preventive Vaccines Market by Disease, 2016-2026, $ mn 91
Table 26. South Korea Preventive Vaccines Market by Administration, 2016-2026, $ mn 92
Table 27. Preventive Vaccines Market in Rest of APAC by Country, 2016-2026, $ mn 94
Table 28. AstraZeneca plc: Company Snapshot 99
Table 29. AstraZeneca plc: Revenue, 2018-2020, $ bn 100
Table 30. Bavarian Nordic A/S: Company Snapshot 102
Table 31. Bavarian Nordic A/S: Marketed Products and Pipeline, as of July 2020 103
Table 32. China National Biotec Group Company Ltd.: Company Snapshot 105
Table 33. CSL Ltd.: Company Snapshot 107
Table 34. Daiichi Sankyo Co. Ltd.: Company Snapshot 109
Table 35. Emergent BioSolutions Inc.: Company Snapshot 111
Table 36. GlaxoSmithKline: Company Snapshot 113
Table 37. GlaxoSmithKline: Business Segmentation 114
Table 38. GlaxoSmithKline: Product Portfolio 115
Table 39. GlaxoSmithKline: Revenue, 2018-2020, $ bn 116
Table 40. GlaxoSmithKline: Recent Developments 116
Table 41. Johnson & Johnson: Company Snapshot 117
Table 42. Johnson & Johnson: Business Segments 118
Table 43. Merck & Co., Inc.: Company Snapshot 119
Table 44. Merck & Co., Inc.: Business Segmentation 119
Table 45. Merck & Co., Inc.: Revenue, 2018-2020, $ bn 120
Table 46. Moderna Inc.: Company Snapshot 121
Table 47. Novavax, Inc.: Company Snapshot 122
Table 48. Pfizer Inc.: Company Snapshot 124
Table 49. Pfizer Inc.: Business Segmentation 125
Table 50. Pfizer Inc.: Product Portfolio 126
Table 51. Pfizer Inc.: Revenue, 2018-2020, $ bn 127
Table 52. Pfizer Inc.: Recent Developments 127
Table 53. Sanofi: Company Snapshot 128
Table 54. Sanofi: Business Segmentation 128
Table 55. Sanofi: Revenue, 2018-2020, $ bn 129
Table 56. Takeda Pharmaceutical Co. Ltd.: Company Snapshot 130
Table 57. Risk Evaluation for Investing in Asia Pacific Market, 2020-2026 133
Table 58. Critical Success Factors and Key Takeaways 136
